EQS-Adhoc: Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide

EQS

Im Artikel erwähnte Wertpapiere: Merck

EQS-Ad-hoc: Merck KGaA / Key word(s): Study results
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide

05-Dec-2023 / 21:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis ("RMS") in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the "Clinical Trials"). Both Clinical Trials, evaluating the efficacy and safety of evobrutinib compared to teriflunomide for up to 156 weeks, did not meet the primary endpoint of reducing annualized relapse rates (ARR) in people with RMS.

Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.


Contact:
Esther Döringer
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151 1454 7809
Email: esther.doeringer@merckgroup.com
Internet: https://www.merckgroup.com/en
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX


End of Inside Information

05-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 (0)6151 72 - 2702
E-mail: Friederike.Segeberg@merckgroup.com
Internet: https://www.merckgroup.com/de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
EQS News ID: 1790011

 
End of Announcement EQS News Service

1790011  05-Dec-2023 CET/CEST

Im Artikel erwähnte Wertpapiere

Merck 152,65 3,39%
close

Populäre Aktien